Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of NH302 in Healthy Participants
NCT07892469Phase 1Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Sep 2026
- Primary completion
- Sep 2027
01
Overview
Phase 1, randomised, double-blind trial of NH302 in pain, sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Incidence of adverse events at Day 7, Incidence of serious adverse events at Day 7 and 10 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
NH302
03
Conditions
pain
Beyond the preview
Go deeper on NCT07892469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892469.